AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- Bayer launches LifeHub UK focused on artificial intelligence to optimize data-driven drug discovery and disease diagnosis
- Nplate® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
- The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
- Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
- Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
Research & Development
- First entirely digital clinical trial encourages physical activity
- New strategy to treat Parkinson's disease
- AI could offer warnings about serious side effects of drug-drug interactions
- Antibody-based eye drops show promise for treating dry eye disease
- Powerful new genomics method can be used to reveal the causes of rare genetic diseases
- AI and big data predict which research will influence future medical treatments
- Pharmacists provide patient value in team-based care
Conferences & Events
- 'FDA should withdraw ANDAs', and 'new technologies could bring massive improvements in efficiency' if implemented correctly
- SMi's 9th Annual Orphan Drugs & Rare Diseases Conference
- SMi's Inaugural Pharmaceutical Manufacturing & Cleanroom Technology Conference
- Disruptive Technologies in Pharma 2019
- Respiratory Drug Delivery 2019
- Exclusive iVeena speaker interview released for 3rd Ophthalmic Drugs Conference
- eyeforpharma The Marketing Disruption Summit
Regulatory Affairs
- FDA approves new treatment for patients with migraine
- FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
- FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
- FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity
- FDA approves first oral GLP-1 treatment for type 2 diabetes